Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 2/20 | 0.72 |
| ▸ | ALK | Q9UM73 | 9/20 | 0.66 |
| ▸ | EGFR | P00533 | 4/20 | 0.66 |
| ▸ | PLK1 | P53350 | 3/20 | 0.65 |
| ▸ | ULK1 | O75385 | 2/20 | 0.61 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.58 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.58 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.58 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.57 |
| ▸ | CDC7 | O00311 | 1/20 | 0.57 |
| ▸ | PLK4 | O00444 | 1/20 | 0.57 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.57 |
| ▸ | AURKA | O14965 | 1/20 | 0.57 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.57 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.57 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.57 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.57 |
| ▸ | JAK2 | O60674 | 1/20 | 0.57 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.57 |
| ▸ | PAK4 | O96013 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16385433 | 0.91 | PTK2 (0.75) | PTK2ALKEGFRPLK1ULK1 | |
| SCHEMBL16371058 | 0.91 | ALK (0.79) | PTK2ALKEGFRPLK1MAPK10 | |
| SCHEMBL17766059 | 0.90 | ALK (0.72) | PTK2ALKEGFRPLK1AURKA | |
| SCHEMBL16385275 | 0.89 | ALK (0.82) | PTK2ALKEGFRPLK1AURKA | |
| SCHEMBL19831500 | 0.88 | PTK2 (0.80) | PTK2ALKEGFRPLK1ULK1 | |
| SCHEMBL17547516 | 0.84 | PTK2 (1.00) | PTK2ALKEGFRPLK1ULK1 | |
| SCHEMBL16371449 | 0.81 | MAPK8 (0.74) | PTK2ALKEGFRPLK1ULK1 | |
| SCHEMBL16371689 | 0.81 | ALK (0.74) | PTK2ALKEGFRPLK1MAPK10 | |
| SCHEMBL16371266 | 0.80 | ALK (0.87) | PTK2ALKEGFRPLK1MAPK10 | |
| SCHEMBL16371316 | 0.80 | ALK (0.87) | PTK2ALKEGFRPLK1MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160145237-A1 | PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE | BETTA PHARMACEUTICALS CO., LTD (CN) | 2016-05-26 | — | — | US | claimed |
| EP-3019489-A1 | PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE | Betta Pharmaceuticals Co., Ltd. (CN) | 2016-05-18 | — | — | EP | claimed |
| WO-2015003658-A1 | PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE | BETTA PHARMACEUTICALS CO., LTD (CN) | 2015-01-15 | — | — | WO | claimed |
| US-10059688-B2 | Protein tyrosine kinase modulators and methods of use | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2018-08-28 | — | — | US | disclosed |
| US-20180009782-A1 | PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2018-01-11 | — | — | US | disclosed |
| US-9783524-B2 | Protein tyrosine kinase modulators and methods of use | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2017-10-10 | — | — | US | disclosed |
| US-9783524-B2 | Protein tyrosine kinase modulators and methods of use | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2017-10-10 | — | — | US | disclosed |
| US-20160145237-A1 | PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE | BETTA PHARMACEUTICALS CO., LTD (CN) | 2016-05-26 | — | — | US | disclosed |
| US-20160145237-A1 | PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE | BETTA PHARMACEUTICALS CO., LTD (CN) | 2016-05-26 | — | — | US | disclosed |
| WO-2015003658-A1 | PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE | BETTA PHARMACEUTICALS CO., LTD (CN) | 2015-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145237-A1 | PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE | ALK, EGFR, ERBB2 | PTK2 308/4885ALK 1/4885EGFR 2/4885 |
| US-10059688-B2 | Protein tyrosine kinase modulators and methods of use | ALK, EGFR, ERBB2 | PTK2 308/4885ALK 1/4885EGFR 2/4885 |
| US-20180009782-A1 | PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE | ALK, EGFR, ERBB2 | PTK2 308/4885ALK 1/4885EGFR 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.